ARCA biopharma, Inc.
(NASDAQ : ABIO)

( )
ABIO After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
Loading ABIO News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-1.00%163.061.3%$781.81m
GILDGilead Sciences, Inc.
0.24%67.261.0%$568.09m
CELGCelgene Corporation
-0.27%124.091.1%$481.61m
BIIBBiogen Inc.
-2.04%268.531.3%$446.03m
REGNRegeneron Pharmaceuticals, Inc.
3.03%394.142.1%$385.16m
INCYIncyte Corporation
-0.14%139.284.3%$353.74m
VRTXVertex Pharmaceuticals Incorporated
20.45%108.012.0%$218.70m
KITEKite Pharma, Inc.
-0.13%78.5117.5%$216.08m
ALXNAlexion Pharmaceuticals, Inc.
1.85%120.721.6%$208.60m
TSROTESARO, Inc.
-1.95%151.8815.6%$193.33m
ILMNIllumina, Inc.
1.08%172.663.4%$164.78m
ESPREsperion Therapeutics, Inc.
-2.44%34.7917.7%$146.82m
CLVSClovis Oncology, Inc.
-3.98%64.3917.2%$135.52m
AUPHAurinia Pharmaceuticals Inc.
1.96%7.308.0%$134.79m
EXELExelixis, Inc.
-0.71%21.135.7%$98.01m

Company Profile

ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company's business combines expertise in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, GencaroTM is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.